Navigation Links
Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
Date:7/10/2013

NEW YORK, July 10, 2013 /PRNewswire/ -- Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The study is a randomized, double blind, placebo controlled study enrolling patients at more than twenty clinical sites in the U.S.

"We are excited to have reached the halfway point in the enrollment of our Squalamine Eye Drop study," said Dr. Irach B. Taraporewala, CEO of Ohr. "This milestone sets the stage for the planned interim analysis once the 60 patients complete the nine month treatment protocol, and we expect the data to be available in the second quarter of 2014."

"I am pleased with the continued progress in the trial to evaluate Squalamine Eye Drops for exudative AMD," commented Dr. Jason Slakter, retinal disease specialist at Vitreous-Retina-Macula Consultants of NY, and member of Ohr's scientific advisory board. "The Company's eye drop for treating wet-AMD would potentially offer patients a convenient, self-administered, treatment alternative or adjunct to currently used intravitreal injections directly into the eye. This could be a significant advancement in the future treatment of wet-AMD."

Study OHR-002 is a randomized, double blind, placebo controlled Phase II study to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD. The study will enroll 120 treatment naive wet-AMD patients at more than twenty clinical sites in the U.S., who will be treated with Squalamine Eye Drops or placebo eye drops twice daily for a nine month period. The primary and secondary endpoints include visual acuity parameters, need for rescue intravitreal inj
'/>"/>

SOURCE Ohr Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 The Academy of Model Aeronautics ... Day on August 15, 2015. National Model Aviation Day was ... to introduce model flying to the general public. , The ... to participate in the celebration by hosting events in their ... National Model Aviation Day events. View our online event ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... BioNorth Texas (BioNorthTX), an independent, ... life sciences industry in northern region of Texas, ... The Foundry in Dallas on April 27, 2015. ... a broad spectrum of biotech professionals from the ... successes in partnering with key life sciences organizations ...
(Date:5/28/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... therapeutics, primarily in the areas of dermatology and ophthalmology, ... 26 million units at a price to the public ... $10.4 million. Each unit consists of (i) one share ... to purchase 0.50 of a share of common stock ...
Breaking Biology Technology:Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3
... American Oriental,Bioengineering (NYSE: AOB ) announced today ... The decision to cancel its,convertible preferred stock offering ... conditions resulting in terms that were not acceptable ... Statements made in this press release are forward-looking ...
... SAN FRANCISCO, Calif., June 5 Exelixis,Inc. (Nasdaq: ... into an,agreement with Deerfield Management, a leading healthcare investment,organization ... $150.0 million in financing through a flexible credit facility. ... next 18 months at Exelixis,discretion. Exelixis is under no ...
... June 5 Cardiac Science,Corporation (Nasdaq: ... cardiac diagnosis,resuscitation, rehabilitation, and informatics products, announced ... Annual Needham & Company Biotechnology,and Medical Technology ... Michael,Matysik, senior vice president and chief financial ...
Cached Biology Technology:Exelixis Receives $150 Million Funding Commitment From Deerfield Management 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 3Exelixis Receives $150 Million Funding Commitment From Deerfield Management 4Exelixis Receives $150 Million Funding Commitment From Deerfield Management 5Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference 2
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... hydrocarbons (PAHs) are components of petroleum products such as ... by-products of the combustion of fuels including petroleum and ... effects. Because they are produced during combustion, they are ... a concern in all urban waterways. However, because there ...
... is gaining credibility in Western medicine for anticancer powers ... of Florida researcher Nam Dang, M.D., Ph.D., and colleagues ... a broad range of lab-grown tumors, including cancers of ... used an extract made from dried papaya leaves, and ...
... Research Centre of Finland will establish a Centre of Water ... water sector is being gathered into one centre. The aim ... water sector in Finland and to create new business opportunities ... centre will be known as the Centre of Water Efficiency ...
Cached Biology News:Sources of pollution in waterways 2Papaya extract thwarts growth of cancer cells in lab tests 2Finland to get a Center of Water Efficiency Excellence 2
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Biology Products: